Ruxolitinib-d9
Ruxolitinib-d9 (INCB18424-d9) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].
Product Specifications
CAS Number
1513883-55-0
Product Name Alternative
INCB18424-d9
UNSPSC
12352005
Target
Apoptosis; Autophagy; Isotope-Labeled Compounds; JAK; Mitophagy
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
N#CC[C@H](C1([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])N2C=C(C=N2)C3=C4C(NC=C4)=NC=N3
Molecular Formula
C17H9D9N6
Molecular Weight
315.42
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (DF1485), CF488A conjugate, 0.1mg/mL
